AWP
PTGX icon

Abacus Wealth Partners’s Protagonist Therapeutics PTGX Stock Holding History

Abacus Wealth Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,094
Closed -$432K – 465
2026
Q1 		$432K Buy
4,094
+331
+9% +$29.3K 0.04% 253
2025
Q4 		$329K Buy
+3,763
New +$308K 0.03% 314

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Abacus Wealth Partners's PTGX Position: Q2 2026 in Review

Abacus Wealth Partners sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 4,094 shares — an estimated $432K sold.

Abacus Wealth Partners first reported a position in PTGX in Q4 2025 and held it in 2 quarters. The position peaked at $432K in Q1 2026. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Abacus Wealth Partners reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Abacus Wealth Partners sold 4,094 Protagonist Therapeutics shares in Q2 2026, an estimated $432K.
  • Abacus Wealth Partners first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 2 quarters.
  • Abacus Wealth Partners's Protagonist Therapeutics position peaked at $432K in Q1 2026.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.